JAK2 and acquired polycythemia vera: These findings extend the work of Putter et al. (2021), who identified molecular genetic alterations in PV patients, including JAK2 mutations and their impact on cellular signaling pathways, but did not examine the downstream metabolic consequences of these genetic defects [80].